INDP

Indaptus Therapeutics, Inc. NASDAQ Listed Aug 4, 2015

Healthcare ·Biotechnology ·US · indaptusrx.com

$2.03

Mkt Cap $3.6M

52w Low $1.51 2.8% of range 52w High $19.91

50d MA $2.20 200d MA $3.37

P/E (TTM) -0.1x

EV/EBITDA 0.3x

P/B 0.7x

Debt/Equity 0.0x

ROE -661.5%

P/FCF -0.2x

RSI (14) —

ATR (14) —

Beta 0.99

50d MA $2.20

200d MA $3.37

Avg Volume 50.5K

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

SIC Code

2834

CIK (SEC)

1857044

Phone

347 480 9760

3 Columbus Circle · New York City, NY 10019 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 17, 2026	AMC	-4.36	-3.10	+28.9%	1.96	+1.5%	-4.6%	-5.9%	-3.4%	+1.8%	-1.7%	—
Nov 12, 2025	AMC	-4.17	-2.98	+28.5%	2.89	-2.8%	+2.4%	-15.2%	-9.6%	+1.8%	-10.4%	—
Aug 13, 2025	AMC	-9.24	-9.09	+1.6%	8.44	-5.8%	-7.5%	-8.8%	+9.0%	-4.3%	-0.1%	—
May 14, 2025	AMC	-11.48	-8.96	+22.0%	11.86	-0.8%	-0.8%	+6.9%	-13.1%	+1.4%	-3.9%	—
Mar 13, 2025	AMC	-0.41	-0.38	+7.3%	22.59	+1.3%	-0.2%	+0.9%	-0.3%	-4.9%	-1.9%	—
Nov 12, 2024	AMC	-0.47	-0.32	+31.9%	32.20	+0.0%	+2.6%	-4.2%	-1.8%	-0.9%	-6.4%	—
Aug 12, 2024	AMC	-0.54	-0.47	+13.0%	47.88	-0.6%	-2.3%	+0.6%	-0.6%	-1.2%	-0.6%	—
May 8, 2024	AMC	-0.57	-0.45	+21.1%	57.96	+1.0%	+1.0%	+2.9%	-1.4%	+0.5%	+6.6%	—
Mar 13, 2024	AMC	-0.54	-0.47	+13.0%	56.00	-3.0%	-4.5%	-2.1%	+3.2%	+6.2%	+13.2%	—
Nov 6, 2023	AMC	-0.55	-0.47	+14.5%	75.04	+6.0%	-10.1%	+6.6%	-10.7%	+1.6%	-4.7%	—
Aug 14, 2023	AMC	-0.58	-0.39	+32.8%	69.44	+0.8%	-9.7%	-3.1%	+10.1%	+1.7%	+0.0%	—
May 11, 2023	AMC	-0.59	-0.51	+13.6%	54.60	+10.3%	+8.2%	-1.4%	-0.5%	-1.0%	+2.0%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Nov 13	Maxim Group	Maintains	Buy → Buy	—	$32.20	$32.20	+0.0%	+2.6%	-4.2%	-1.8%	-0.9%	-6.4%
Oct 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$35.56	$37.24	+4.7%	+12.6%	+8.4%	-2.6%	-2.6%	+29.9%
Jun 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$69.16	$68.60	-0.8%	+6.9%	-5.7%	-6.8%	-3.0%	-1.3%
Apr 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$77.56	$82.60	+6.5%	-5.4%	+6.5%	-4.7%	-5.3%	-6.3%
Sep 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$110.60	$111.16	+0.5%	-11.4%	-4.9%	-18.6%	-8.1%	+11.6%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$69.44	$70.00	+0.8%	-9.7%	-3.1%	+10.1%	+1.7%	+0.0%
Aug 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$61.88	$61.32	-0.9%	+4.1%	+7.8%	-9.7%	-3.1%	+10.1%
Aug 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$51.80	$48.72	-5.9%	-3.2%	+0.6%	+22.8%	+4.1%	+7.8%
May 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$73.08	$73.64	+0.8%	-4.6%	-0.8%	-2.4%	-16.2%	+6.4%
Mar 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$45.36	$47.04	+3.7%	+3.7%	-3.6%	+3.1%	+8.4%	+5.0%
Mar 8	HC Wainwright & Co.	Maintains	Overweight → Overweight	—	$46.48	$46.48	+0.0%	-0.6%	-2.4%	+5.0%	-0.6%	-6.5%
Feb 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$48.44	$49.00	+1.2%	-1.2%	+1.8%	-2.9%	+1.2%	+0.0%
Oct 19	Maxim Group	Upgrade	Hold → Buy	—	$211.12	$228.48	+8.2%	+3.6%	+1.5%	-2.8%	-7.0%	+0.3%

Data updated apr 25, 2026 3:33pm · Source: massive.com